Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
03/2003
03/12/2003EP1290021A2 Polynucleotide sequence encoding a putative cell adhesion molecule
03/12/2003EP1290017A2 Compositions and methods for delivery of a molecule into a cell
03/12/2003EP1290016A2 Vaccine for congenital tremors in pigs
03/12/2003EP1290015A2 Epididymis-specific proteins with fibronectin type ii modules
03/12/2003EP1290007A2 Secreted proteins and polynucleotides encoding them
03/12/2003EP1289568A2 Combination product for carrying out a cytotoxic treatment in a mammal
03/12/2003EP1289567A2 Lyophilizable and enhanced compacted nucleic acids
03/12/2003EP1289566A1 Ubiquitin promoter in vectors for gene therapy in respiratory tract
03/12/2003EP1289553A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
03/12/2003EP1289552A2 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
03/12/2003EP1289546A1 Combined preparation for the treatment of neoplasic diseases
03/12/2003EP1289472A2 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
03/12/2003EP1289368A1 Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
03/12/2003EP0871757B1 Conditionally replicating viral vectors and their use
03/12/2003EP0787016B1 Secretory leukocyte protease inhibitor (slpi) as an inhibitor of tryptase
03/12/2003EP0669973B1 Biological factors and neural stem cells
03/12/2003CN1402793A Lentiviral triplex DNA, and vectors and recombinant cells contg. same
03/12/2003CN1402785A Novel compounds
03/12/2003CN1402784A Cell proliferation inhibitory protein, polynucleotide, antisense polynucleotide to polynucleotide, and cell proliferation inhibitors, cancer diagnostics, cancer remedies and compositions
03/12/2003CN1402782A MAGE-A12 antigenic peptides and uses thereof
03/12/2003CN1402780A 感染性克隆 Infectious clone
03/12/2003CN1402733A Angiogenic proteins and uses thereof
03/12/2003CN1401778A Recombinant of viral vector and human tumor suppressor gene, and use thereof
03/12/2003CN1401657A Gene sequence and use of fish testicle development factor
03/12/2003CN1401656A Gene sequence and use of fish testicle development factor
03/12/2003CN1401392A Liver cancer superantigen immunogene therapy agent
03/12/2003CN1401387A Tumor suppressing polypeptide TSF and gene therapy vector composition
03/11/2003US6531584 Nuclease resistant oligonucleotide analogs; DNA or RNA modulation; diagnosis, thearpy of viral diseases
03/11/2003US6531456 Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors
03/11/2003US6531455 Delivery of polynucleotides by secretory gland expression
03/11/2003US6531313 Invasive bacterial vectors for expressing alphavirus replicons
03/11/2003US6531312 Isolated nucleic acid of given sequence
03/11/2003US6531307 Capable of activating a compound with little or no toxicity into an active product; use in treating viral diseases, cancer, and genetic disorders
03/11/2003US6531292 Genes and proteins controlling cholesterol synthesis
03/11/2003US6531285 Automated detection apparatus with a conveying means for test columns
03/11/2003US6531280 Method for identifying or isolating a molecule and molecules identified thereby
03/11/2003US6531135 Administering to the subject an effective amount of a composition comprising a population of infectious, defective alphavirus particles in a pharmaceutically acceptable carrier
03/11/2003US6531124 Genetically engineered cells to deliver insulinotropin to stimulate insulin release, to increase insulin sensitivity in peripheral tissues, or to inhibit glucagon secretion from the pancreas
03/11/2003CA2109085C Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
03/06/2003WO2003019136A2 Methods for inhibiting angiogenesis
03/06/2003WO2003018836A2 Model of autoimmune disease and methods for identifying agents against autoimmune disease
03/06/2003WO2003018823A1 Obesity related genes expressed at least in the hypotalamus, liver or pancreas
03/06/2003WO2003018821A2 Compositions and methods for treating neurodegenerative diseases
03/06/2003WO2003018815A2 Regulation of human g protein-couple receptor kinase
03/06/2003WO2003018806A1 Novel human bmcc1 gene
03/06/2003WO2003018799A2 Modulators of bone homeostasis identified in a high-throughput screen
03/06/2003WO2003018788A2 Improved nitroreductase enzymes
03/06/2003WO2003018770A2 Amplified oncogenes and their involvement in cancer
03/06/2003WO2003018768A2 Transmembrane protein differentially expressed in cancer
03/06/2003WO2003018755A2 Wild-type ras as a cancer therapeutic agent
03/06/2003WO2003018751A2 Apparatus and method for electroporation of biological samples
03/06/2003WO2003018636A2 Chimaeric peptides of insulin, their compositions and use in treating diabetes
03/06/2003WO2003018630A1 Nucleic acid and polypeptide linked to breast cancer and uses therefor
03/06/2003WO2003018611A2 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
03/06/2003WO2003018603A1 Aminoglycoside lipid derivatives for transfection
03/06/2003WO2003018134A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003WO2003018065A1 Anti-cancer agents comprising disintegrin genes and the treating methods
03/06/2003WO2003018064A2 Lipophilic drug compositions
03/06/2003WO2003018055A1 Vaccine using papilloma virus e proteins delivered by viral vector
03/06/2003WO2003018044A1 New drug
03/06/2003WO2003018033A1 Use of fucans in the treatment of adhesions, arthritis and psoriasis
03/06/2003WO2003017944A2 Gpi-anchored cytokines
03/06/2003WO2003017943A2 Therapeutic compositions and methods for treating viral infection
03/06/2003WO2003017940A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption
03/06/2003WO2002099097A8 Novel compounds for chemiluminescense procedures
03/06/2003WO2002096469A3 Gene delivery via a baculovirus vector
03/06/2003WO2002092122A3 Use of osteopontin for the treatment and/or prevention of neurologic diseases
03/06/2003WO2002088327A9 Methods for viral oncoapoptosis in cancer therapy
03/06/2003WO2002088319A3 Mini-adenoviral vector and methods of using same
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002081709A3 Modified hpv e6 and e7 genes and proteins useful for vaccination
03/06/2003WO2002074908A3 Methods and reagents for regulating apoptosis
03/06/2003WO2002074249A3 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
03/06/2003WO2002062959A3 Hepatitis b virus treatment
03/06/2003WO2002062845A3 Adhesion molecules
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002057293A3 Modified zinc finger binding proteins
03/06/2003WO2002053753A3 Novel human lipase and polynucleotides encoding the same
03/06/2003WO2002051994A8 Polypeptides
03/06/2003WO2002031151A3 Lipocalins
03/06/2003WO2002022080A9 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
03/06/2003WO2002020748A2 Host cells for packing a recombinant adeno-associated virus (raav), method for the production and use thereof
03/06/2003WO2002014500A3 Human genes and gene expression products
03/06/2003WO2002012325A3 Suppressor gene
03/06/2003WO2002010401A3 18431 and 32374, human protein kinase family members and uses therefor
03/06/2003WO2002000914A9 Bioengineered vehicles for targeted nucleic acid delivery
03/06/2003WO2001098361A9 Agonist anti-trk-c monoclonal antibodies
03/06/2003WO2001098343A9 Conserved diaphanous-related formin autoregulatory domain (dad)
03/06/2003WO2001074900A9 Nuclear factor kb inducing factor
03/06/2003WO2001072781A9 Human genes and expression products
03/06/2003WO2001066596A9 Human fgf-23 gene and gene expression products
03/06/2003WO2001062924A9 Human g protein-coupled receptors
03/06/2003WO2001055393A9 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
03/06/2003WO2001038488A3 Gene expression by positive feedback activation of a cell type-specific promoter
03/06/2003US20030045830 Inhibiting the expression of a specific gene involved in eye function by inducing or reverting a mutation in that gene by topically applying or injecting the chimeric oligonucleotide
03/06/2003US20030045686 Mutein polypeptide for use in the treatment of hypoxia and ischemic related tissue damages
03/06/2003US20030045498 Contacting the ocular cell with an expression vector comprising the nucleic acid sequence encoding the inhibitor of angiogenesis and the nucleic acid sequence encoding the neurotrophic agent.
03/06/2003US20030045497 Nucleotide sequence wherein one or two cytosines in at least one CpG motif has been replaced with a cytosine analogue resistant to methylation.
03/06/2003US20030045496 Treating tumor cells with a selenium prodrug lyase and a selenium-containing prodrug such as selenocysteine, selenohomocysteine, selenomethionine or selenoethionine.
03/06/2003US20030045495 Method for selective expression of therapeutic genes by hyperthermia
1 ... 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 ... 870